Abstract
Each year large pharmaceutical companies produce massive amounts of primary screening data for lead discovery. To make better use of the vast amount of information in pharmaceutical databases, companies have begun to scrutinize the lead generation stage to ensure that more and better qualified lead series enter the downstream optimization and development stages. This article describes computational techniques for end to end analysis of large drug discovery screening sets. The analysis proceeds in three stages: In stage 1 the initial screening set is filtered to remove compounds that are unsuitable as lead compounds. In stage 2 local structural neighborhoods around active compound classes are identified, including similar but inactive compounds. In stage 3 the structure-activity relationships within local structural neighborhoods are analyzed. These processes are illustrated by analyzing two large, publicly available databases.
Keywords: Large Screening Sets, pharmaceutical databases
Current Drug Discovery Technologies
Title: Systematic Analysis of Large Screening Sets in Drug Discovery
Volume: 1 Issue: 1
Author(s): Paul E. Blower Jr., Kevin P. Cross, Michael A. Fligner, Glenn J. Myatt, Joseph S. Verducci and Chihae Yang
Affiliation:
Keywords: Large Screening Sets, pharmaceutical databases
Abstract: Each year large pharmaceutical companies produce massive amounts of primary screening data for lead discovery. To make better use of the vast amount of information in pharmaceutical databases, companies have begun to scrutinize the lead generation stage to ensure that more and better qualified lead series enter the downstream optimization and development stages. This article describes computational techniques for end to end analysis of large drug discovery screening sets. The analysis proceeds in three stages: In stage 1 the initial screening set is filtered to remove compounds that are unsuitable as lead compounds. In stage 2 local structural neighborhoods around active compound classes are identified, including similar but inactive compounds. In stage 3 the structure-activity relationships within local structural neighborhoods are analyzed. These processes are illustrated by analyzing two large, publicly available databases.
Export Options
About this article
Cite this article as:
Blower Jr. E. Paul, Cross P. Kevin, Fligner A. Michael, Myatt J. Glenn, Verducci S. Joseph and Yang Chihae, Systematic Analysis of Large Screening Sets in Drug Discovery, Current Drug Discovery Technologies 2004; 1 (1) . https://dx.doi.org/10.2174/1570163043484879
DOI https://dx.doi.org/10.2174/1570163043484879 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Development of Epigenetics and Related Inhibitors for Targeted Drug Design in Cancer Therapy
Current Topics in Medicinal Chemistry Intercalation of Erlotinib and Pemetrexed in the Treatment of Non-Small Cell Lung Cancer
Current Drug Targets The Role of Major Histocompatibility Complex Polymorphisms in the Incidence and Outcome of Non-Hodgkin Lymphoma
Current Immunology Reviews (Discontinued) 3D-QSAR and Docking Studies on 2-acyliminobenzimidazoles Derivatives as Potent ALK Inhibitors
Letters in Drug Design & Discovery Involvement of Endoplasmic Reticulum Stress in Isoliquiritigenin-Induced SKOV-3 Cell Apoptosis
Recent Patents on Anti-Cancer Drug Discovery Potential Therapeutic Application of Chondroitin Sulfate/Dermatan Sulfate
Current Drug Discovery Technologies Main Anti-tumor Angiogenesis Agents Isolated From Chinese Herbal Medicines
Mini-Reviews in Medicinal Chemistry Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms
Current Neuropharmacology Structural Basis for Therapeutic Intervention of uPA/uPAR System
Current Drug Targets A New Frontier in the Treatment of Cancer: NK-1 Receptor Antagonists
Current Medicinal Chemistry Oxidative Stress in the Cochlea: An Update
Current Medicinal Chemistry Isoform-Selective PI3K Inhibitors for Various Diseases
Current Topics in Medicinal Chemistry Mutant B-Raf Kinase Inhibitors as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Biological and Chemical Aspects of Natural Biflavonoids from Plants: A Brief Review
Mini-Reviews in Medicinal Chemistry Xenograft models of primary acute myeloid leukemia for the development of imaging strategies and evaluation of novel targeted therapies.
Current Pharmaceutical Biotechnology Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer
Current Cancer Drug Targets Bladder Cancer Chemopreventive Agents: Current Knowledge and Concepts
Mini-Reviews in Medicinal Chemistry Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer
Current Medicinal Chemistry Camptothecins and Topoisomerase I; A Foot in the Door. Targeting the Genome Beyond Topoisomerase I with Camptothecins and Novel Anticancer Drugs; Importance of DNA Replication, Repair and Cell Cycle Checkpoints
Current Medicinal Chemistry - Anti-Cancer Agents The Expanding Role of Tumor Necrosis Factor-α Inhibitors in the Management of Rheumatic Diseases
Medicinal Chemistry Reviews - Online (Discontinued)